Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

Verified by: AstraZeneca, January 2011
First Received: March 7, 2008 | Last Updated: January 24, 2011 | Phase: Phase 3 | Start Date: June 1999
Overall Status: Completed | Estimated Enrollment: 734
  • …
  • Tell a FriendPrint

A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular...

Brief Summary

Official Title: “Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function”

A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
  • Study Primary Completion Date: May 2003

Intervention(s) in this Clinical Trial

  • Drug: Candesartan
  • Drug: Placebo

Arms, Groups and Cohorts in this Clinical Trial

  • Active Comparator: 1
  • Placebo Comparator: 2

Outcome Measures for this Clinical Trial

Primary Measures

  • Cardiovascular mortality or hospitalisation due to congestive heart failure
    • Time Frame: , 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Secondary Measures

  • Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI
    • Time Frame: Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Male or female aged 18 or above
  • Congestive Heart Failure with symptoms for more than 4 weeks before starting study
  • Provision of informed consent

Exclusion Criteria:

  • Current low blood pressure with symptoms
  • Liver disease considered significant by the study doctor
  • Pregnant or lactating females

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: AstraZeneca Industry

Overall Clinical Trial Officials and Contacts

Dr Salim Yusuf Principal Investigator   

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00634712

Study ID Number: SH-AHS-0007

ClinicalTrials.gov Identifier: NCT00634712

Health Authority: United States: Food and Drug Administration

  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00634712